Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
IPO Year:
Exchange: NYSE
Website: bostonscientific.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/16/2025 | $118.00 | Outperform | Leerink Partners |
4/16/2025 | $113.00 | Hold → Buy | Needham |
1/10/2025 | $108.00 | Hold → Buy | Deutsche Bank |
10/18/2024 | Buy → Hold | Needham | |
5/30/2024 | $90.00 | Buy | Goldman |
2/1/2024 | $65.00 → $80.00 | Neutral → Buy | Mizuho |
7/19/2023 | $59.00 | Outperform | Robert W. Baird |
6/30/2023 | $64.00 | Buy | CL King |
5/30/2023 | $58.00 | Overweight | Morgan Stanley |
3/29/2023 | $57.00 | Buy | UBS |